The EU’s Proposed Restricitive Nicotine Policies Seem all the More Ridiculous in the Face of Sweden’s Success

There is a widening policy rift across Europe. On one side, there is a large and growing body of scientific evidence in support of tobacco harm reduction. On one hand, the European Commission is pushing an excessively restrictive regulatory agenda that threatens to roll back progress in reducing smoking. Central to this debate is the issue: should all nicotine products be treated equally, irrespective of their risk profile? And the answer to that question is, of course, a definitive no.

Yet this is precisely what the European Union’s current trajectory indicates. Proposed changes to tobacco laws seem headed for stricter limits on vaping, nicotine pouches, and other reduced-risk alternatives. These range from flavour bans, higher taxes and broader classification frameworks that view all nicotine products alongside combustible cigarettes.

This argument is often presented as a precaution, specifically fears regarding youth uptake and nicotine dependence. But it misses a critical distinction: combustion is the key driver of smoking-related disease, not nicotine, even if it is addictive.

Ignoring this detail is particularly worrying when mounted against the large, growing body of evidence indicating vaping and other non-combustible nicotine products are proving effective as a smoking cessation tool. Independent analyses from the Cochrane Collaboration for instance, have consistently shown that nicotine vapes are more effective than conventional nicotine replacement products like patches and gum in helping smokers quit. And countries that have embraced this evidence are already achieving results they can measure.

The United Kingdom, for instance, has incorporated vaping into its public health approach, resulting in greater quit success and faster declines in smoking. But the most significant example comes from Sweden, where daily smoking has now been reduced to the lowest level ever recorded, at only 3.7 percent. Sweden took the pragmatic route, one of harm reduction — allowing access to lower-risk alternatives, like snus, nicotine pouches, and vaping products, rather than waging a war against smokers with punitive measures like taxes or overly restrictive bans on smoking.

Yet at the EU level, this evidence is frequently discounted or quoted selectively. In their reports, they concede lower levels of toxicant exposure from alternatives, then jump to potential risk, introducing a new dimension that warrants increased restrictions. That leaves a policy narrative that centers around uncertainty rather than proven successes. Meanwhile, Sweden has done what the rest of Europe (and the rest of the world) is still working toward: reaching a smoke-free status.

The cost of the EU’s current approach is not theoretical — it exists in economic and behavioral reality. So when safer alternatives are more expensive, less accessible, or just a less appealing option, it gives smokers less incentive to switch. This can undermine cessation rates or even result in unintended consequences like continued cigarette smoking and the expansion of unregulated markets.

Disappointingly, that’s already happening. In some European states, restrictive measures on vaping and nicotine products have been introduced in parallel to stubborn smoking rates and the development of illicit trade routes. Such outcomes undermine both public health and regulatory goals.

A more detailed look at recent EU policy discussions reveals an alarming trend. The scientific evidence for why harm reduction works is well established, yet it has not been fully translated into actionable policy recommendations. At the same time, less substantiated fears — including so-called “gateway effect” — are treated with undue rigor even as youth smoking rates have dipped steadily across the continent.

This gap between the evidence and how policy is being shaped creates a disconnect.

Some experts say this reflects a broader ideological opposition to nicotine itself, rather than an objective analysis of relative risk. If true, this would be a fundamental shift away from outcome-based public health and toward a more prohibitionist model. And the stakes could not be higher.

Tobacco use continues to be the number one cause of preventable death in Europe, killing hundreds of thousands a year. It is thus one of the most pressing public health priorities — accelerating the decline in smoking. Policies that instead inhibit access to effective cessation tools — and fail to support this goal — risk extending the burden of smoking-related disease for yet another generation.

In contrast, countries that embrace risk-proportionate approaches are showing what’s possible. Sweden is the most vivid example, but not the only one. Other countries that took this approach to harm reduction are also showing more rapid declines in smoking, and the message could not be clearer: policy needs to follow science.

Policymakers need to understand the risk continuum of different nicotine products and facilitate access to lower-risk options for adult smokers. Hence, they should regulate proportionately rather than uniformly and focus on real-world outcomes rather than theoretical concerns.

The EU still has a chance to recalibrate its strategy. It can accelerate the path to a smoke-free future by leveraging proven models and applying the full force of science. The battle over nicotine policy in Europe is by no means concluded. But one thing is becoming increasingly clear: Restrictive, one-size-fits-all approaches are not providing the results necessary to end smoking. Sweden has shown what works. The question now is whether the rest of Europe is willing to open its eyes — or follow through on a course that threatens to undo one of the most hopeful public health strategies in a generation.

https://www.vapingpost.com/2026/01/30/the-cost-of-bad-science-how-flawed-studies-and-anti-nicotine-bias-are-shaping-european-tobacco-policy/